Pancreas after kidney transplants in posturemic XXXX with @entity6 .

@entity1 @entity7971 @entity6 @entity205 @entity1140
Pancreas after previous kidney (PAK) transplants are an attractive option for type 1 @entity6 @entity1 because of the short waiting time and use of living kidney donors. Factors associated with the increased success rate of PAK transplants in four immunosuppressive eras were analyzed. Between July 1, 1978, and April 30, 2000, 406 PAK transplants were performed in posturemic @entity1 . Four immunosuppressive eras were analyzed: (1) the precyclosporine @entity7971 , @entity7971 1 (n = 65; 16%); (2) the @entity205 @entity7971 , @entity7971 2 (n = 109; 27%); (3) the @entity1140 @entity7971 with monoclonal or polyclonal antibody induction therapy, @entity7971 3 (n = 104; 26%); and (4) the @entity1140 @entity7971 with monoclonal and polyclonal antibody induction therapy, @entity7971 4 (n = 128; 31%). @entity1 and graft survival, rejection, and technical failure rates were calculated. @entity1 survival rates have remained high over time, from 91% ( @entity7971 1) to 96% ( @entity7971 4) at 1 yr posttransplant. Pancreas graft survival rates with primary cadaver transplants have significantly increased, from 17% ( @entity7971 1) to 81% ( @entity7971 4) at 1 yr. The rate of graft loss from rejection has significantly decreased, from 78% ( @entity7971 1) to 9% ( @entity7971 4) at 1 yr. Results were best when donors and recipients were matched for at least one antigen per HLA locus. Kidney graft survival was higher in PAK transplant recipients compared with @entity6 recipients of kidney transplants alone from the time of the kidney as well as the pancreas transplants. PAK recipients now enjoy >80% graft survival at 1 yr. This improvement in outcome results from better immunosuppression, good matching, and close posttransplant monitoring for rejection.
